首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   236729篇
  免费   16321篇
  国内免费   668篇
耳鼻咽喉   2401篇
儿科学   6369篇
妇产科学   4664篇
基础医学   33903篇
口腔科学   5595篇
临床医学   22065篇
内科学   47318篇
皮肤病学   3714篇
神经病学   23654篇
特种医学   9461篇
外国民族医学   23篇
外科学   33776篇
综合类   1659篇
现状与发展   1篇
一般理论   253篇
预防医学   23233篇
眼科学   4295篇
药学   14714篇
中国医学   356篇
肿瘤学   16264篇
  2023年   1012篇
  2022年   1571篇
  2021年   4108篇
  2020年   2794篇
  2019年   4249篇
  2018年   5251篇
  2017年   4119篇
  2016年   4522篇
  2015年   5070篇
  2014年   7266篇
  2013年   9785篇
  2012年   15244篇
  2011年   15726篇
  2010年   8646篇
  2009年   8402篇
  2008年   14130篇
  2007年   14665篇
  2006年   14136篇
  2005年   13490篇
  2004年   12436篇
  2003年   11521篇
  2002年   10633篇
  2001年   5746篇
  2000年   5410篇
  1999年   5274篇
  1998年   2973篇
  1997年   2400篇
  1996年   2286篇
  1995年   1929篇
  1994年   1761篇
  1993年   1650篇
  1992年   3443篇
  1991年   3141篇
  1990年   2947篇
  1989年   2758篇
  1988年   2546篇
  1987年   2252篇
  1986年   2119篇
  1985年   2066篇
  1984年   1568篇
  1983年   1349篇
  1982年   926篇
  1981年   801篇
  1980年   679篇
  1979年   1056篇
  1978年   701篇
  1977年   612篇
  1974年   569篇
  1973年   574篇
  1972年   544篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children.  相似文献   
6.
7.
8.
9.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号